Currently viewing the tag: "sovereign immunity"

On July 20, 2018, the Federal Circuit decided the matter of Saint Regis Mohawk Tribe and Allergan v. Mylan Pharmaceuticals Inc., where the petitioners (Allergan) attempted to terminate an inter partes review (IPR) challenge in the USPTO by asserting tribal sovereign immunity. In St. Regis, Allergan, a pharmaceutical company, moved to dismiss Mylan’s IPR challenge [...]

Continue Reading